Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis
This clinical trial evaluates the efficacy of Denosumab, an anti-RANKL monoclonal antibody, in improving bone mineral density (BMD) in patients with osteoporosis due to systemic mastocytosis. The study is sponsored by Assistance Publique - Hôpitaux de Paris and involves a randomized, double-blind design comparing Denosumab to a placebo over three years.
Indication: Osteoporosis
Modality: monoclonal antibody
Target: Osteoporosis associated with systemic mastocytosis
Sponsor: Assistance Publique - Hôpitaux de Paris
Source URL: ClinicalTrials.gov
Source updated: Mar 31, 2026
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Osteoporosis associated with systemic mastocytosis
View original source fields
Condition raw: Osteoporosis
Condition normalized: Osteoporosis
Modality raw: Osteoporosis
Modality normalized: monoclonal antibody
Target raw: Osteoporosis associated with systemic mastocytosis
Target normalized: Osteoporosis associated with systemic mastocytosis